Use of tocilizumab in kidney transplant recipients with COVID-19
from Wiley Online Library
Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm with large interleukin 6 release. The IL‐6‐receptor blocker tocilizumab may control the aberrant host immune response in COVID‐19 patients. In this pandemic, kidney transplant recipients are a high‐risk population for severe infection and showed poor outcomes. Researchers present a multicenter cohort study of 80 KT patients with severe COVID‐19 treated with tocilizumab during hospital admission.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063